Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-includes/feed-rss2.php on line 8
CASI – US Market Buzz http://www.usmarketbuzz.com Nation and Economy Mon, 20 Jul 2020 16:28:22 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.23 Are You Investing Into The Biotech Dip? CASI Pharmaceuticals Inc (NASDAQ:CASI), Global Equity International Inc (OTCBB:GEQU), SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) http://www.usmarketbuzz.com/are-you-investing-into-the-biotech-dip-casi-pharmaceuticals-inc-nasdaqcasi-global-equity-international-inc-otcbbgequ-scivac-therapeutics-inc-otcmktssvacf-3297 Thu, 15 Oct 2015 12:50:02 +0000 http://www.usmarketbuzz.com/?p=3297 On Wednesday Richmond Federal Reserve President Jeffrey Lacker stated a brief occurrence of upsetting economic information that has done little to alter his outlook for the U.S economy. Lacker, who voted for an interest rate increase in September against the majority of Fed policymakers who choose to keep rates steady, stated he has not decided on how he will vote at the Oct. 27th-28th meeting. Although he was not persuade much by a slowdown in job growth and weaker-than-expected retail sales in September. “It doesn’t change my outlook much,” he told Fox Business in an interview hopefully his stance doesn’t impact the value of biotech stock such as:

CASI Pharmaceuticals Inc (NASDAQ:CASI) is a public, biopharma company dedicated to certain therapeutics that focus on cancer and other unmet medical needs. In a recent announcement CASI Pharmaceuticals Inc (NASDAQ:CASI) revealed that its oncology drug candidate, ENMD-2076 received Orphan Drug designation from the European Medicines Agency for the treatment of hepatocellular carcinoma (HCC), including fibrolamellar carcinoma, a rare type of HCC. In the past 30 days beginning on September 15 to October 14th CASI has seen a large increase in price of 78.43%. This new designation gives CASI 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there. The product was previously granted Orphan Drug designation for the treatment of HCC by US Food and Drug Administration last year and provides CASI with a 7-year market exclusivity in the country after its New Drug Application approval.

Why Are Investors Scrambling For Shares Of THIS Biotechnology Stock?

Global Equity International Inc (OTCBB:GEQU) through its wholly-owned subsidiary Global Equity Partners Plc., advises worldwide business leaders with their most crucial decisions and opportunities dealing with growth, capital needs, structure and the development of a global presence. With locations in Dubai and London, Global Equity has built a strong relationships in the US, UK, Central Europe, the Middle East and South East Asia to help clients in realizing their full value and potential by bringing them to external capital and resources that place an emphasis on collaborative thinking. Global Equity International Inc (OTCBB:GEQU) Is very pleased to release the news about a strategic partnership agreement with the “Middle East Prospect Exhibition” (“MEPEX” -www.mepexonline.com), to work as their exclusive selected Financial Partner for capital raising, Advisory and Public Listings for all of the MEPEX participants. GEQU has seen a major price increase in the past 3 months of 1022.73% making them a penny stock to watch for shareholders invested in the biotech sector.

WHAT BIOTECH STOCK ARE STREET ANALYSTS CALLING “THE NEXT WINNING STOCK”?

SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) Who’s headquarters are located in Rehovot Israel, is in the business of developing, manufacturing and promoting biological products for human healthcare. The Company’s flagship product, Sci‐B‐Vac™, is a recombinant 3rd generation hepatitis B vaccine. SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) announced that its wholly-owned subsidiary SciVac Ltd. has obtained the go-ahead from the Israeli Ministry of Health to progress further on all standard manufacturing,involving labeling and release of Sci-B-Vac(TM) to the market, following corrective actions to the automated labeling system and a overview of the Company’s facilities earlier in the month of September. SVACF is up from last Friday’s close increasing 13% following highs of $0.0195 on Tuesday. In past announcements, it was noted that Opko Health, Inc. (OPKO) had a 45% stake in SciVac. Sci-B-Vac has displaying a performance in 20+ company-sponsored or investigator- initiated trials, dealing with more than 5000 who have enrolled while also being administered to over 500,000 patients to date, with favorable safety and efficacy profiles according to company data.

]]>